A low molecular weight dextran sulphate, ILB ®, for the treatment of amyotrophic lateral sclerosis (ALS): An open-label, single-arm, single-centre, phase II trial

Srinivasan, Venkataramanan, Homer, Victoria, Barton, Darren, Clutterbuck-James, Abigail, Jenkins, Siân, Potter, Claire, Brock, Kristian, Logan, Ann, Smith, Donna, Bruce, Lars, Nagy, Zsuzsanna and Bach, Simon P. 2024. A low molecular weight dextran sulphate, ILB ®, for the treatment of amyotrophic lateral sclerosis (ALS): An open-label, single-arm, single-centre, phase II trial. PLoS ONE 19 (7) , e0291285. 10.1371/journal.pone.0291285

	PDF (Appendix 1: ALS trial protocol) - Supplemental Material Download (18MB)
	PDF (TREND Statement Checklist) - Supplemental Material Download (420kB)
	PDF (Article) - Published Version Download (2MB)
	PDF (Appendix 2: Sample version of the ALS trial patient information sheet) - Supplemental Material Download (862kB)

Abstract

Background: Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig´s disease, is a rare neurological condition and is the most common motor neurone disease. It is a fatal disease with specific loss of motor neurons in the spinal cord, brain stem, and motor cortex leading to progressive paralysis and usually death within five years of diagnosis. There remains no cure for ALS, and management is focused on a combination of neuroprotective medication, respiratory support, and management by multidisciplinary clinics. Patients and methods: This prospective, single-arm, open-label phase II clinical trial of sustained weekly administration of 2 mg/kg ILB® (a low-molecular weight dextran sulphate) was conducted in a single UK hospital. Eligible patients were at least 18 years and had a definite diagnosis of ALS according to El Escorial Criteria. The co-primary outcomes were safety, tolerability, and quantity of ILB® administered. EudraCT number. 2018-000668-28 Findings: Between 18-Apr-2019 and 27-Mar-2020, 11 patients were recruited and treated for up to 38 weeks. There were no treatment terminations or withdrawals. One serious adverse event was reported, which was not related to ILB® and resolved without sequalae. 270 mild/moderate adverse events were reported with no intolerable events occurring during the trial. The total number of ILB® treatments administered per patient ranged from 4 to 38, with a cumulative dose ranging from 745 to 6668 mg. As a result of the COVID-19 pandemic and the high-risk status of study participants, recruitment and treatment was suspended early in Mar-2020. At the long-term follow-up, three patients had died after the trial was halted, between 53 and 62 weeks after their final ILB® injection. Interpretation: Long-term weekly ILB® injections of 2 mg/kg was well tolerated and had an acceptable safety profile in patients with ALS. Trial registration: EudraCT: 2018-000668-28. clinicaltrials.gov: NCT03705390. This trial adheres to the principles of GCP in the design, conduct, recording and reporting of clinical trials as listed in part 2, “Conditions and Principles which apply to all Clinical Trials” under the header “Principles based on Articles 2 to 5 of the EU GCP Directive” in the Medicines for Human Use Clinical Trials Regulations (as amended in SI 2006/1928). For clarity, the study did not conform to all aspects of the International Conference on Harmonisation (ICH) E6 R2 Guidelines for GCP (also known as ‘ICH GCP’). Of note, we did not use an external database, perform 100% source data verification, and only primary outcome data were analysed in parallel by a second, independent statistician.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Medicine Centre for Trials Research (CNTRR)
Additional Information:	License information from Publisher: LICENSE 1: URL: http://creativecommons.org/licenses/by/4.0/
Publisher:	Public Library of Science
ISSN:	1932-6203
Date of First Compliant Deposit:	12 July 2024
Date of Acceptance:	2 June 2024
Last Modified:	12 Jul 2024 08:30
URI:	https://orca.cardiff.ac.uk/id/eprint/170543

Actions (repository staff only)

Edit Item